RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
RenovoRx, Inc.NASDAQ: RNXT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$3.52M, compared with -$2.42M a year earlier. Trailing-twelve-month EBITDA was -$12.27M.
Context
- EBITDA amounted to 994.3% of revenue in FY2025, down 19503.4 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$9.19M (+17.7%) for the fiscal year ending Dec 2026, a step up from the -26.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.52M-19.7% QoQ
- Last fiscal yearDec 2025
- -$11.17M-26.7% YoY
- LTMMar 2026
- -$12.27M-63.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -45.5% | -5.9% | +39.6 pp |
| 1 year | -26.7% | +17.7% | +44.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (11.17M) USD
- Year-over-year change
- -26.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.17M) | -26.7% |
| FY2024 | 2024-12-31 | (8.81M) | +12.9% |
| FY2023 | 2023-12-31 | (10.12M) | -3.0% |
| FY2022 | 2022-12-31 | (9.83M) | -79.3% |
| FY2021 | 2021-12-31 | (5.48M) | — |
EBITDA vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's LTM Mar 2026 EBITDA of -$12.27M is the highest of the 6 companies compared; the peer median is -$32.68M.
- Its year-over-year change of -63.0% is the 5th highest of 6, against a peer median of -50.5%.
- EBITDA amounts to 823.9% of revenue for RNXT, versus a peer median of 292.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$12.27M | -63.0% | — | 823.9% | |
| LTM Mar 2026 | -$14.89M | -54.8% | — | — | |
| LTM Mar 2026 | -$15.9M | +19.8% | — | — | |
| LTM Mar 2026 | -$32.68M | -11.5% | — | — | |
| LTM Mar 2026 | -$40.92M | -50.5% | — | — | |
| LTM Dec 2025 | -$77.62M | -86.2% | — | 292.4% | |
| Peer median (excluding RNXT) | -$32.68M | -50.5% | — | 292.4% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 43K | 1.12M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 327K |
| Gross Profit | 0 | 0 | 0 | 43K | 796K |
| Gross Margin | — | — | — | 100.0% | 70.9% |
| Research & Development | 3.04M | 4.3M | 5.67M | 6.03M | 6.27M |
| Selling, General & Admin | 2.63M | 5.65M | 5.73M | 4.99M | 7.04M |
| Operating Expenses | 5.67M | 9.95M | 11.4M | 11.01M | 13.31M |
| Depreciation & Amortization | 9K | 6K | 6K | 0 | 2K |
| EBITDA | (5.48M) | (9.83M) | (10.12M) | (8.81M) | (11.17M) |
| EBITDA Margin | — | — | — | -20497.7% | -994.3% |
| Operating Income | (5.67M) | (9.95M) | (11.4M) | (10.97M) | (12.51M) |
| Operating Margin | — | — | — | -25511.6% | -1114.0% |
| Interest Income | 70K | 57K | 0 | 384K | 427K |
| Interest Expense | 904K | 57K | 108K | 0 | 0 |
| Other Income / Expenses | (653K) | 61K | 1.16M | 2.16M | 1.34M |
| Income Before Tax | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Pre-Tax Margin | — | — | — | -20497.7% | -994.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Net Margin | — | — | — | -20497.7% | -994.5% |
| EPS (Basic) | (0.40) | (0.54) | (0.50) | (0.37) | (0.32) |
| EPS (Diluted) | (0.40) | (0.54) | (0.50) | (0.37) | (0.32) |
| Weighted Avg Shares | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M |
| Weighted Avg Shares (Diluted) | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M |
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.